| Identification | Back Directory | [Name]
Amg 517 | [CAS]
659730-32-2 | [Synonyms]
CS-691
Amg 517
AMG517; AMG-517
N-[4-[[6-[4-(Trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]acetamide
AcetaMide, N-[4-[[6-[4-(trifluoroMethyl)phenyl]-4-pyriMidinyl]oxy]-2-benzothiazolyl]-
N-(4-((6-(4-(Trifluoromethyl)phenyl)pyrimidin-4-yl)oxy)benzo[d]thiazol-2-yl)acetamide
N-[4-[[6-[4-(Trifluoromethyl)phenyl]-4-pyrimidinyl]oxy]-2-benzothiazolyl]acetamide AMG517 | [Molecular Formula]
C20H13F3N4O2S | [MDL Number]
MFCD14584859 | [MOL File]
659730-32-2.mol | [Molecular Weight]
430.4 |
| Chemical Properties | Back Directory | [Melting point ]
227℃ | [density ]
1.458 | [storage temp. ]
Store at -20°C | [solubility ]
≥21.5 mg/mL in DMSO; insoluble in H2O; ≥4.93 mg/mL in EtOH | [form ]
solid | [pka]
10.19±0.70(Predicted) | [color ]
White to off-white | [InChI]
1S/C20H13F3N4O2S/c1-11(28)26-19-27-18-15(3-2-4-16(18)30-19)29-17-9-14(24-10-25-17)12-5-7-13(8-6-12)20(21,22)23/h2-10H,1H3,(H,26,27,28) | [InChIKey]
YUTIXVXZQIQWGY-UHFFFAOYSA-N | [SMILES]
FC(F)(F)c1ccc(cc1)c2ncnc(c2)Oc3c4nc([s]c4ccc3)NC(=O)C |
| Hazard Information | Back Directory | [Uses]
AMG-517 is a novel TRPV1 antagonist. | [Biological Activity]
AMG517 is an orally activehighly potent and selective vanilloid receptor-1 (TRPV1; VR1; capsaicin receptor) antagonist th at blocks TRPV1-mediated cellular Ca2+ influx (h/r/m IC50/stimulant = 0.76 nM/1.01 nM/1.9 nM/500 nM capsaicin; 0.62 nM/0.5 nM/0.63 nM/acid (pH 5) using respective CHO transfectants; IC50 >20 μM against TRPV2/3/4TRPA1and TRPM8-mediated responses; <45% binding at 10 μM to 87 receptorsenzymesand ion channels) and exhibits antihyperalgesic efficacy in vivo (capsaicin-induced flinch = ED50 = 0.33 mg/kg ratsp.o.; CFA-induced thermal hyperalgesiaMED = 0.83 mg/kg ratsp.o.). | [in vivo]
AMG 517 is shown to be effective in a rodent "on-target" biochemical challenge model (capsaicin-induced flinch, ED50=0.33 mg/kg p.o.) and is antihyperalgesic in a model of inflammatory pain (CFA-induced thermal hyperalgesia, MED=0.83 mg/kg, p.o.)[1].The minimally effective dose is 0.3 mg/kg for AMG 517 and the corresponding plasma concentration is 90 ng/mL. Oral administration of AMG 517 reverses established thermal hyperalgesia in a dose-dependent manner at 21 h after CFA injection. AMG 517 causes transient hyperthermia in rodents, dogs, and monkeys. AMG 517 induces hyperthermia in a steep dose-dependent manner, with 0.3, 1, and 3 mg/kg associated with 0.5, 0.6, and 1.6°C increases in body temperature, respectively. Body temperatures of rats treated with all doses of AMG 517 return to baseline within 10 to 20 h[2]. | [storage]
Store at +4°C |
|
|